Title: SENATE BILL 29 By: Hamilton
Official Title: SENATE BILL 29 By: Hamilton
Number of Sections: 3
Source: versions - Introduced
Media Type: application/pdf
Strikethrough Detection: 2 sections found

================================================================================

Section 1:
1
STATE OF OKLAHOMA
1
2
1st Session of the 60th Legislature (2025)
2
3
3
4
4
5
5
6
AS INTRODUCED
6
7
An Act relating to health care; requiring licensed
7
practitioners to offer pharmacogenomic test prior to
8
prescription of psychotropic drugs; requiring certain
8
disclosures and obtainment of informed consent;
9
directing order and administration of pharmacogenomic
9
test; providing for codification; and providing an
10
effective date.
10
11
11
12
12
13
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
13
14

Section 2:
SECTION 1. NEW LAW A new section of law to be codified
14
15
in the Oklahoma Statutes as Section 7201 of Title 63, unless there
15
16
is created a duplication in numbering, reads as follows:
16
17
A. A licensed practitioner shall, prior to the prescription of
17
18
any psychotropic drug to a patient, offer to administer a
18
19
pharmacogenomic test to the patient for the purpose of guiding the
19
20
decisions of the licensed practitioner with respect to how the
20
21
patient’s genes may react to certain medications.
21
22
B. The licensed practitioner shall, to the best of the licensed
22
23
practitioner’s knowledge, inform the patient of the efficacy of
23
24
pharmacogenomic testing. The licensed practitioner shall inform the
24
Req. No. 496 Page 1
1
patient of whether or not the pharmacogenomic test to be
1
2
administered is approved by the United States Food and Drug
2
3
Administration. The licensed practitioner shall obtain the
3
4
patient’s informed consent prior to ordering a pharmacogenomic test.
4
5
If the practitioner is aware of the cost of the pharmacogenomic
5
6
test, the practitioner shall provide an estimate to the patient of
6
7
such cost.
7
8
C. If a patient provides informed consent to receive a
8
9
pharmacogenomic test, the licensed practitioner shall order the
9
10
pharmacogenomic test and administer such test to the patient prior
10
11
to the prescription of any psychotropic medication.
11
12

Section 3:
SECTION 2. This act shall become effective November 1, 2025.
12
13
13
14
60-1-496 DC 12/16/2024 12:38:56 PM
14
15
15
16
16
17
17
18
18
19
19
20
20
21
21
22
22
23
23
24
24
Req. No. 496 Page 2
[DELETED:  P B H]
[DELETED:  P D 1]


================================================================================

Raw Text:
1
STATE OF OKLAHOMA
1
2
1st Session of the 60th Legislature (2025)
2
3
SENATE BILL 29 By: Hamilton
3
4
4
5
5
6
AS INTRODUCED
6
7
An Act relating to health care; requiring licensed
7
practitioners to offer pharmacogenomic test prior to
8
prescription of psychotropic drugs; requiring certain
8
disclosures and obtainment of informed consent;
9
directing order and administration of pharmacogenomic
9
test; providing for codification; and providing an
10
effective date.
10
11
11
12
12
13
BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:
13
14
SECTION 1. NEW LAW A new section of law to be codified
14
15
in the Oklahoma Statutes as Section 7201 of Title 63, unless there
15
16
is created a duplication in numbering, reads as follows:
16
17
A. A licensed practitioner shall, prior to the prescription of
17
18
any psychotropic drug to a patient, offer to administer a
18
19
pharmacogenomic test to the patient for the purpose of guiding the
19
20
decisions of the licensed practitioner with respect to how the
20
21
patient’s genes may react to certain medications.
21
22
B. The licensed practitioner shall, to the best of the licensed
22
23
practitioner’s knowledge, inform the patient of the efficacy of
23
24
pharmacogenomic testing. The licensed practitioner shall inform the
24
Req. No. 496 Page 1

1
patient of whether or not the pharmacogenomic test to be
1
2
administered is approved by the United States Food and Drug
2
3
Administration. The licensed practitioner shall obtain the
3
4
patient’s informed consent prior to ordering a pharmacogenomic test.
4
5
If the practitioner is aware of the cost of the pharmacogenomic
5
6
test, the practitioner shall provide an estimate to the patient of
6
7
such cost.
7
8
C. If a patient provides informed consent to receive a
8
9
pharmacogenomic test, the licensed practitioner shall order the
9
10
pharmacogenomic test and administer such test to the patient prior
10
11
to the prescription of any psychotropic medication.
11
12
SECTION 2. This act shall become effective November 1, 2025.
12
13
13
14
60-1-496 DC 12/16/2024 12:38:56 PM
14
15
15
16
16
17
17
18
18
19
19
20
20
21
21
22
22
23
23
24
24
Req. No. 496 Page 2

[DELETED:  P B H]
[DELETED:  P D 1]